Followers | 47 |
Posts | 12038 |
Boards Moderated | 0 |
Alias Born | 09/12/2017 |
![](https://investorshub.advfn.com/uicon/633016.png?cb=1702783483)
Friday, April 05, 2024 11:29:05 AM
Why was there no Principal Investigator listed under the Study Details tab and clearly shows No information provided
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
CytoDyn, Inc.
Collaborators
No information provided
Investigators
No information provided
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8
Hmmm, 18 Study Locations and not one single Principal Investigator listed right? RIGHT?
United States
Alabama Locations
Alexander City, Alabama, United States, 35010
Advanced Cardiovascular, LLC
California Locations
Fullerton, California, United States, 92835
St. Jude Medical Center
Los Angeles, California, United States, 90095
UCLA
Florida Locations
Tampa, Florida, United States, 33612
James A. Haley Veterans' Hospital
Georgia Locations
Gainesville, Georgia, United States, 30501
Center for Advanced Research & Education (CARE)
Massachusetts Locations
Boston, Massachusetts, United States, 02215
Beth Israel Deaconess Medical Center
New Jersey Locations
Livingston, New Jersey, United States, 07052
St. Barnabas
Morristown, New Jersey, United States, 07962-1905
Atlantic Health System Hospital
Teaneck, New Jersey, United States, 07666
Holy Name Medical Center
New York Locations
Bronx, New York, United States, 10467
Montefiore Medical Center
Brooklyn, New York, United States, 11229
New York Community Hospital of Brooklyn
North Carolina Locations
Winston-Salem, North Carolina, United States, 27103
Novant Health
Ohio Locations
Columbus, Ohio, United States, 43215
Ohio Health
Oregon Locations
Corvallis, Oregon, United States, 97330
Good Samaritan Hospital Corvallis
Portland, Oregon, United States, 97239
Oregon Health and Sciences University
Texas Locations
Dallas, Texas, United States, 75204
Baylor Scott & White Research Institute
Houston, Texas, United States, 77030
Baylor College of Medicine
Houston, Texas, United States, 77030
University of Texas
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8
And misiu, just one more thing, says here in that same study under the Researcher Tab "Information provided by CytoDyn, Inc." with no other independent person/entity that would attach their name to the data---
ClinicalTrials.gov ID NCT04347239
Sponsor CytoDyn, Inc.
Information provided by CytoDyn, Inc. (Responsible Party)
Last Update Posted 2022-01-14
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8&tab=table
18 study locations, 394 patients with numerous doctors and "Information provided by CytoDyn, Inc." seem a little odd to you?
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM